The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a suggestion that it did prevent new or worsening heart failure.

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

Proposed in the early 1980s as a solution for managing complications of portal hypertension, the percutaneous creation of ...

The FINEARTS-HF study included 46% women, showing finerenone's efficacy in reducing cardiovascular events in HFmrEF/HFpEF ...

In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone, a nonsteroidal mineralocorticoid ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

In the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF), finerenone reduced the risk of the primary end point similarly in women and ...

In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, resulted in more frequent hyperkalemia and less ...

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

In January 2021, Bayer AG announced the USA FDA priority review for their New Drug Application for Finerenone drug used to treat patients with chronic kidney disease and associated Type 2 diabetes.

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.